{"title":"肌醇对多囊卵巢综合征患者辅助生殖技术结果的影响：随机临床试验研究的系统回顾和荟萃分析","authors":"Azadeh Akbari Sene, Maryam Saeedzarandi, Maryam Yazdizadeh, Seyede Razieh Ghaffari, Fatemehsadat Amjadi, Zahra Zandieh, Yousef Moradi","doi":"10.18502/ijrm.v23i5.19260","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Conflicting evidence from clinical trials on the effects of myo-inositol and D-chiro-inositol on assisted reproductive technology (ART) outcomes in women with polycystic ovarian syndrome (PCOS) necessitates a systematic review and meta-analysis.</p><p><strong>Objective: </strong>To evaluate the effect of myo-inositol and D-chiro-inositol on ART outcomes in women with PCOS.</p><p><strong>Materials and methods: </strong>A comprehensive search was conducted in PubMed, Scopus, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Library for studies published from January 2000-2023. Statistical analyses were performed using STATA version 17.</p><p><strong>Results: </strong>17 intervention studies were included. myo-inositol/D-chiro-inositol supplementation significantly increased the clinical pregnancy rate (RR: 1.64, 95% CI: 1.25-2.15; I<sup>2</sup> = 13.5%; p = 0.32) and top-grade embryos (RR: 1.12, 95% CI: 1.02-1.23; I<sup>2</sup> = 85.43%; p = 0.0001). However, it was associated with reductions in antral follicle count (WMD: -0.78, 95% CI: -1.07 to -0.49; I<sup>2</sup> = 97.37%; p = 0.001) and anti-Mullerian hormone levels (WMD: -0.46, 95% CI: -0.67 to -0.25; I<sup>2</sup> = 91.95%; p = 0.001).</p><p><strong>Conclusion: </strong>This meta-analysis provides reliable evidence on the effects of myo-inositol/D-chiro-inositol on fertility and ovarian function in women with PCOS undergoing ART.</p>","PeriodicalId":14386,"journal":{"name":"International Journal of Reproductive Biomedicine","volume":"23 5","pages":"353-376"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413536/pdf/","citationCount":"0","resultStr":"{\"title\":\"The effect of myo-inositol on assisted reproductive technology outcomes in women with polycystic ovarian syndrome: A systematic review and meta-analysis of randomized clinical trial studies.\",\"authors\":\"Azadeh Akbari Sene, Maryam Saeedzarandi, Maryam Yazdizadeh, Seyede Razieh Ghaffari, Fatemehsadat Amjadi, Zahra Zandieh, Yousef Moradi\",\"doi\":\"10.18502/ijrm.v23i5.19260\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Conflicting evidence from clinical trials on the effects of myo-inositol and D-chiro-inositol on assisted reproductive technology (ART) outcomes in women with polycystic ovarian syndrome (PCOS) necessitates a systematic review and meta-analysis.</p><p><strong>Objective: </strong>To evaluate the effect of myo-inositol and D-chiro-inositol on ART outcomes in women with PCOS.</p><p><strong>Materials and methods: </strong>A comprehensive search was conducted in PubMed, Scopus, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Library for studies published from January 2000-2023. Statistical analyses were performed using STATA version 17.</p><p><strong>Results: </strong>17 intervention studies were included. myo-inositol/D-chiro-inositol supplementation significantly increased the clinical pregnancy rate (RR: 1.64, 95% CI: 1.25-2.15; I<sup>2</sup> = 13.5%; p = 0.32) and top-grade embryos (RR: 1.12, 95% CI: 1.02-1.23; I<sup>2</sup> = 85.43%; p = 0.0001). However, it was associated with reductions in antral follicle count (WMD: -0.78, 95% CI: -1.07 to -0.49; I<sup>2</sup> = 97.37%; p = 0.001) and anti-Mullerian hormone levels (WMD: -0.46, 95% CI: -0.67 to -0.25; I<sup>2</sup> = 91.95%; p = 0.001).</p><p><strong>Conclusion: </strong>This meta-analysis provides reliable evidence on the effects of myo-inositol/D-chiro-inositol on fertility and ovarian function in women with PCOS undergoing ART.</p>\",\"PeriodicalId\":14386,\"journal\":{\"name\":\"International Journal of Reproductive Biomedicine\",\"volume\":\"23 5\",\"pages\":\"353-376\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12413536/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Reproductive Biomedicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18502/ijrm.v23i5.19260\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Reproductive Biomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijrm.v23i5.19260","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：关于肌醇和d -肌醇对多囊卵巢综合征（PCOS）女性辅助生殖技术（ART）结果影响的临床试验证据相互矛盾，有必要进行系统回顾和荟萃分析。目的：探讨肌醇和d -手性肌醇对PCOS患者ART治疗效果的影响。材料和方法：综合检索PubMed、Scopus、Web of Science、EMBASE、ClinicalTrials.gov和Cochrane Library，检索2000-2023年1月发表的研究。使用STATA version 17进行统计分析。结果：纳入17项干预研究。肌-肌醇/ d -肌-肌醇的补充显著提高了临床妊娠率（RR: 1.64, 95% CI: 1.25 ~ 2.15; I2 = 13.5%; p = 0.32）和优质胚胎（RR: 1.12, 95% CI: 1.02 ~ 1.23; I2 = 85.43%; p = 0.0001）。然而，它与窦卵泡计数（WMD: -0.78, 95% CI: -1.07至-0.49;I2 = 97.37%, p = 0.001）和抗苗勒管激素水平（WMD: -0.46, 95% CI: -0.67至-0.25;I2 = 91.95%, p = 0.001）的减少有关。结论：本荟萃分析为肌醇/ d -手性肌醇对接受ART治疗的PCOS患者生育能力和卵巢功能的影响提供了可靠的证据。
The effect of myo-inositol on assisted reproductive technology outcomes in women with polycystic ovarian syndrome: A systematic review and meta-analysis of randomized clinical trial studies.
Background: Conflicting evidence from clinical trials on the effects of myo-inositol and D-chiro-inositol on assisted reproductive technology (ART) outcomes in women with polycystic ovarian syndrome (PCOS) necessitates a systematic review and meta-analysis.
Objective: To evaluate the effect of myo-inositol and D-chiro-inositol on ART outcomes in women with PCOS.
Materials and methods: A comprehensive search was conducted in PubMed, Scopus, Web of Science, EMBASE, ClinicalTrials.gov, and the Cochrane Library for studies published from January 2000-2023. Statistical analyses were performed using STATA version 17.
Results: 17 intervention studies were included. myo-inositol/D-chiro-inositol supplementation significantly increased the clinical pregnancy rate (RR: 1.64, 95% CI: 1.25-2.15; I2 = 13.5%; p = 0.32) and top-grade embryos (RR: 1.12, 95% CI: 1.02-1.23; I2 = 85.43%; p = 0.0001). However, it was associated with reductions in antral follicle count (WMD: -0.78, 95% CI: -1.07 to -0.49; I2 = 97.37%; p = 0.001) and anti-Mullerian hormone levels (WMD: -0.46, 95% CI: -0.67 to -0.25; I2 = 91.95%; p = 0.001).
Conclusion: This meta-analysis provides reliable evidence on the effects of myo-inositol/D-chiro-inositol on fertility and ovarian function in women with PCOS undergoing ART.
期刊介绍：
The International Journal of Reproductive BioMedicine (IJRM), formerly published as "Iranian Journal of Reproductive Medicine (ISSN: 1680-6433)", is an international monthly scientific journal for who treat and investigate problems of infertility and human reproductive disorders. This journal accepts Original Papers, Review Articles, Short Communications, Case Reports, Photo Clinics, and Letters to the Editor in the fields of fertility and infertility, ethical and social issues of assisted reproductive technologies, cellular and molecular biology of reproduction including the development of gametes and early embryos, assisted reproductive technologies in model system and in a clinical environment, reproductive endocrinology, andrology, epidemiology, pathology, genetics, oncology, surgery, psychology, and physiology. Emerging topics including cloning and stem cells are encouraged.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
